Pratteln, Switzerland, April 30, 2021 -- Santhera Pharmaceuticals (SIX: 
SANN) announces that it has issued 2,312,000 treasury shares. 
 
   On April 30, 2021, Santhera completed the ordinary capital increase 
resolved on March 18, 2021, by issuing 312,000 new treasury shares for 
purposes of the planned restructuring of the CHF 60 million convertible 
bond 2017-2022 (ISIN CH0353955195) and potentially for other purposes. 
At the same time, 2,000,000 shares were issued out of the existing 
authorized capital as treasury shares. The newly created registered 
shares will initially be held as treasury shares in order to fulfill 
obligations arising from Santhera's financing instruments. After the 
capital increases, Santhera's share capital amounts to 26,201,136 
shares. 
 
   The new shares will be listed as per May 3, 2021. 
 
   About Santhera 
 
   Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical 
company focused on the development and commercialization of innovative 
medicines for rare neuromuscular and pulmonary diseases with high unmet 
medical need. Santhera has an exclusive license for all indications 
worldwide to vamorolone, a first-in-class dissociative steroid with 
novel mode of action, currently investigated in a pivotal study in 
patients with DMD as an alternative to standard corticosteroids. The 
clinical stage pipeline also includes lonodelestat (POL6014) to treat 
cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well 
as an exploratory gene therapy approach targeting congenital muscular 
dystrophies. Santhera out-licensed ex-North American rights to its first 
approved product, Raxone(R) (idebenone), for the treatment of Leber's 
hereditary optic neuropathy (LHON) to Chiesi Group. For further 
information, please visit www.santhera.com. 
 
   Raxone(R) is a trademark of Santhera Pharmaceuticals. 
 
   For further information please contact: 
 
   public-relations@santhera.com 
https://www.globenewswire.com/Tracker?data=o-Z_rVGILyjFn_69m6V6zG2mXDbvaukhrE59D0Fm8b_YGPa3M3-bGU3VILI0aYzMRxGplsv6CnjWdAEw64sTln61xZZVXokdrDeMhplT7U_bMC_MeqcN1YdtjehGjfL5 
or 
 
   Eva Kalias, Head External Communications 
 
   Phone: +41 79 875 27 80 
 
   eva.kalias@santhera.com 
 
   Disclaimer / Forward-looking statements 
 
   This communication does not constitute an offer or invitation to 
subscribe for or purchase any securities of Santhera Pharmaceuticals 
Holding AG. This publication may contain certain forward-looking 
statements concerning the Company and its business. Such statements 
involve certain risks, uncertainties and other factors which could cause 
the actual results, financial condition, performance or achievements of 
the Company to be materially different from those expressed or implied 
by such statements. Readers should therefore not place undue reliance on 
these statements, particularly not in connection with any contract or 
investment decision. The Company disclaims any obligation to update 
these forward-looking statements. 
 
   # # # 
 
   Attachment 
 
 
   -- 2021 04 30_CapIncreaseFinancings_e_final 
      https://ml-eu.globenewswire.com/Resource/Download/453c2561-4312-4497-971f-0a8fa4d30d70

(END) Dow Jones Newswires

April 30, 2021 11:45 ET (15:45 GMT)